AUTHORS
Arianna Jean Smith, B.S. Biotechnology, Cody William Carter, BS, MS2, Pradeep Ramalingam, MD PhD3, Jason Butler, Ph.D.4
AFFILIATIONS
1 University of Florida, Gainesville, United States
2 University of Florida, Gainesville, United States
3 University of Florida, Gainesville, United States
4 University of Florida, Gainesville, United States
ABSTRACT
Hematopoietic stem cells (HSCs) reside within the specialized bone marrow (BM) perivascular niche, where external signals modulate quiescence, self-renewal, and differentiation. This niche has been difficult to recapitulate ex vivo, and many current HSC expansion products remain enriched for exhausted HSCs and differentiated progenitors rather than bona fide, transplantable stem cells. BM endothelial cells (BMECs) are a critical source of angiocrine factors that support HSC function, including stem cell factor (SCF) and NOTCH ligands. We have previously developed a serum free ex vivo expansion platform utilizing a murine BMEC feeder layer to isolate and dissect the direct effects of endothelial cell (EC)-derived angiocrine signals on hematopoietic stem and progenitor cells (HSPCs), enabling identification of therapeutic targets and mechanistic dissection of niche biology.
Thrombospondin-1 (Thbs1) is a well characterized anti-angiogenic factor that we have recently shown to negatively affect hematopoietic function. Indeed, global Thbs1 knockout mice (Thbs1gKO) show superior HSC engraftment relative to wild-type (WT) counterparts in competitive transplant assays. Thbs1 is secreted by multiple cells within the BM, including hematopoietic and BM niche cells. Utilizing Thbs1 conditional deletion models, we have found that EC-specific Thbs1 deletion recapitulated the Thbs1gKO phenotype. To dissect how Thbs1 loss affects ECs themselves, we isolated primary BMECs from WT, Thbs1gKO, and Thbs1-GFP reporter mice, where the GFP knock-in/knock-out allowed real-time tracking of Thbs1 expression.
We first characterized how the loss of Thbs1 may affect EC's ability to recover from injury through a scratch wound assay. We found that Thbs1gKO and Thbs1-GFP BMECs recovered faster than WT controls, with most wounds being completely closed at 48 hours in contrast to 72 hours for controls. Longitudinal tracking of GFP expression revealed a steady decline over 72 hours followed by a sharp spike at 96 hours, with expression concentrated at the wound interface during healing and persisting at the closed seam thereafter. These preliminary data suggest Thbs1 acts as a ‘brake’ that limits angiogenesis once healing is complete, while its unexpected enrichment at the active wound interface may nonetheless contribute to the accelerated healing observed in Thbs1gKO and Thbs1-GFP BMECs.
To test the direct effect of EC-Thbs1 on HSPCs, 25,0000 HSPCs were cultured with WT or Thbs1gKO BMECs and expanded for 9 days in StemSpan and SCF. Thbs1gKO BMEC co-cultures yielded larger expansion products enriched for myeloid and HPC-2 populations. In competitive transplants (100,000 CD45+ expanded product with 500,000 competitor cells), engraftment of CD45+ product from Thbs1gKO BMEC co-cultures significantly exceeded WT at both early (4-week) and late (16-week) timepoints.
Collectively, these data establish that EC-derived Thbs1 both regulates angiogenesis and directly suppresses HSPC function. The superior expansion and engraftment achieved with Thbs1gKO BMEC co-culture identifies Thbs1 as a tractable therapeutic target for improving ex vivo HSPC expansion and transplant outcomes. Cord blood is an attractive graft source for patients with malignant hematologic disease given its tolerance of HLA mismatch and accessibility, but low HSC counts and poor ex vivo expansion of bona fide HSCs remains major barriers, contributing to relapse and infection risk. Ongoing work in human umbilical vein endothelial cell co-cultures will test the translational potential of this platform and further define Thbs1’s mechanistic role in vascular and hematopoietic recovery.
DISCLOSURES
Arianna Jean Smith, B.S. Biotechnology: No relevant conflicts of interest to declare.